A lot of the uncertainty surrounding the Phase 2 results would have been avoided if PYMX had just included the data from Slide 13 in the press release. That would have allowed investors to quickly compare the April data with the 92% figure from December.
That was the biggest goof, because most investors just skimmed thru the press release, saw the 70-89% numbers, and figured the results were lower than in December. Only in the conf call did they see the data using the criteria in December, and that the data was actually BETTER (91-97%) than in December (92%).
The other mistake was not fully explaining the drop off in the mid-dose data. In the conf call, the CMO said it was due to the smaller number of patients in that arm, but it wasn't until the annual shareholder meeting a week later that we learned it was mainly due to several patients in that arm who had responded to treatment but who hadn't returned for the later evaluation, and therefore had to erroneously be considered treatment failures. This should have been explained at the April 23 conf call, and there would have been no confusion concerning the mid-dose arm data.
Also, the May 1 annual shareholders meeting should have been webcast, allowing Nic and the CMO to clarify everything. As it was, we had to rely upon second hand info from Yahoo posters.
News 
Market Data 
Discover 
